Mizuno,Y et al.(2008),“Progress in the pathogenesis and genetics of Parkinson's disease”,Philos Trans R Soc Lond B Biol Sci363: 2215-27,PMID 18426756full text
de Lau,LM;Giesbergen,PC;de Rijk,MC;Hofman,A;Koudstaal,PJ;Breteler,MM(2004),“Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study”,Neurology63: 1240-4,PMID 15477545
Yamawaki,M;Kusumi,M;Kowa,H;Nakashima,K(2009).“Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century”.Neuroepidemiology32(4): 263-269.doi:10.1159/000201565.PMID19209006.
Dorsey, E. Ray et al.(Mar 2023).“Trichloroethylene: An Invisible Cause of Parkinson’s Disease?”.Journal of Parkinson's Disease13(2): 203-218.doi:10.3233/JPD-225047.
Hellenbrand W, Boeing H, Robra BP, Seidler A, Vieregge P, Nischan P, Joerg J, Oertel WH, Schneider E, Ulm G(Sep 1996).“Diet and Parkinson's disease. II: A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study”.Neurology47(3): 644-650.PMID8797457.
Etminan,M;Gill,SS;Samii,A(Jun 2005).“Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis”.Lancet Neurol4(6): 362-365.PMID15907740.
Knekt,Paul;Kilkkinen, Annamari; Rissanen, Harri; Marniemi, Jukka; Saaksjarvi, Katri; Heliovaara, Markku(2010).“Serum Vitamin D and the risk of Parkinson disease”.Arch Neurol67(7): 808-811.doi:10.1001/archneurol.2010.120.
Hernan,MA;Takkouche,B;Caamano-Isorna,F;Gestal-Otero,JJ(Sep 2002).“A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease”.Ann Neurol52(3): 276-284.PMID12205639.
Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC(Jul 2001).“Prospective study of caffeine consumption and risk of Parkinson's disease in men and women”.Ann Neurol50(1): 56-63.PMID11456310.
Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR(May 2000).“Association of coffee and caffeine intake with the risk of Parkinson disease”.JAMA283(20): 2674-2679.PMID10819950.
Gagne,JJ;Power,MC(Mar 2010).“Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis”.Neurology74(12): 995-1002.doi:10.1212/WNL.0b013e3181d5a4a3.PMID20308684.
Aarsland,D, et al(1999),“Range of neuropsychiatric disturbances in patients with Parkinson's disease”,J Neurol Neurosurg Psychiatry67: 492-6,PMID 10486397
Kirsch-Darrow,L;Fernandez,HH;Marsiske,M;Okun,MS;Bowers,D(2006),“Dissociating apathy and depression in Parkinson disease”,Neurology67: 33-8,PMID 16832074
PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. The Lancet, Early Online Publication, 11 June 2014. doi:10.1016/S0140-6736(14)60683-8
Zanettini,R;Antonini,A;Gatto,G;Gentile,R;Tesei,S;Pezzoli,G(2007),“Valvular heart disease and the use of dopamine agonists for Parkinson's disease”,NEJM356: 39-46,PMID 17202454full text
Seppi,K;Weintraub,D;Coelho,M;Perez-Lloret,S;Fox,SH;Katzenschlager,R;Hametner,EM;Poewe,Wet al.(Oct 2011).“The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease”.Mov Disord26 Supple 3: S42-80.doi:10.1002/mds.23884.PMID22021174.
Bar Am,O;Amit,T;Youdim,MB(Jan 2004).“Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline”.Neurosci Lett355(3): 169-172.PMID14732458.
Bar-Am,O;Amit,T;Youdim,MB(Oct 2007).“Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro”.J neurochem103(2): 500-508.PMID17635668.
Parkinson Study Group(Dec 2002).“A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study”.Arch Neurol59(12): 1937-1943.PMID1247018.
Rascol,O;Fitzer-Attas,CJ;Hauser,R;Jankovic,J;Lang,A;Langston,JW;Melamed,E;Poewe,Wet al.(May 2011).“A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes”.Lancet Neurol10(5): 415-423.doi:10.1016/S1474-4422(11)70073-4.PMID21482191.
Parkinson Study Group(Feb 2005).“A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study”.Arch Neurol62(2): 241-248.PMID15710852.
Murata,M;Hasegawa,K;Kanazawa,I;The Japan Zonisamide on PD Study Group(Jan 2007).“Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.”.Neurology68(1): 45-50.PMID17200492.
Djaldetti,Ruth;Giladi,Nir;Hassin-Baer,Sharon;Shabtai,Hertzel;Melamed,Eldad(2003-11).“Pharmacokinetics of Etilevodopa Compared to Levodopa in Patient's With Parkinson's Disease: An Open-label, Randomized, Crossover Study”.Clinical Neuropharmacology26(6): 322-326.PMID14646613.
Hickey,P;Stacy,M(2011).“Available and emerging treatments for Parkinson's disease: a review”.Drug design, development and therapy5: 241-254.doi:10.2147/DDDT.S11836.PMID21607020.
Eggert K, Squillacote D, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W; German Competence Network on Parkinson's Disease(May 2010).“Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study”.Mov Disord25(7): 896-905.doi:10.1002/mds.22974.PMID20461807.
Asanuma,M;Miyazaki,I;Ogawa,N(2003).“Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease”.Neurotox Res5(3): 165-176.PMID12835121.
Shapira,AH;Olanow,CW(Dec 2008).“Drug selection and timing of initiation of treatment in early Parkinson's disease”.Ann Neurol64(Suppl2): S47-55.doi:10.1002/ana.21460.PMID19127579.
Wernig,M, et al(2008),“Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease”,Proc Natl Acad Sci U S A105: 5856-61,PMID 18391196
Post,B;Merkus,MP;de Haan,RJ;Speelman,JD; CARPA study group(2007),“Prognostic factors for the progression of Parkinson's disease: a systematic review”,Mov Disord22: 1839-51,PMID 17595026
Hatano,T;Kubo,S;Sato,S;Hattori,N(Dec 2009).“Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease”.J Neurochem111(5): 1075-1093.doi:10.1111/j.1471-4159.2009.06403.x.PMID19780902.
Singleton AB, Farrer M, Johnson J, et al(2003).“alpha-Synuclein locus triplication causes Parkinson's disease”.Science302(5646): 841.doi:10.1126/science.1090278.PMID14593171.
Yamamura,Y;Sobue,I;Ando,K;Iida,M;Yanagi,T(Mar 1973).“Paralysis agitans of early onset with marked diurnal fluctuation of symptoms”.Neurology23(3): 239-244.PMID4735177.
Kitada,T;Asakawa,S;Hattori,N;Matsumine,H;Yamamura,Y;Minoshima,S;Yokochi,M;Mizuno,Yet al.(Apr 1998).“Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism”.Nature392(6676): 605-608.PMID9560156.
Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J(Jun 2006).“Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin”.Nature441(7097): 1157-1161.PMID16672980.
Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, Seol JH, Yoo SJ, Hay BA, Guo M(Jun 2006).“Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin”.Nature441(7097): 1162-1166.PMID16672981.
Smith WW, Pei Z, Jiang H, Moore DJ, Liang Y, West AB, Dawson VL, Dawson TM, Ross CA(2005).“Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration”.Proceedings of the National Academy of Sciences of the United States of America102(51): 18676–18681.doi:10.1073/pnas.0508052102.PMID16352719.
Funayama,M;Hasegawa,K;Kowa,H;Saito,M;Tsuji,S;Obata,F(2002),“A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1”,Ann Neurol51: 296-301,PMID 11891824
Hampshire,DJ;Roberts,E;Crow,Y;Bond,J;Mubaidin,A;Wriekat,AL;Al-Din,A;Woods,CG(2001),“Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36.”,J Med Genet38: 680-682,PMID 11584046full text
Cuervo,AM;Stefanis,L;Fredenburg,R;Lansbury,PT;Sulzer,D(Aug 2004).“Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy”.Science305(5688): 1292-1295.PMID15333840.
Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, Goebel I, Mubaidin AF, Wriekat AL, Roeper J, Al-Din A, Hillmer AM, Karsak M, Liss B, Woods CG, Behrens MI, Kubisch C(Oct 2006).“Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPas”.Nat Genet38(10): 1184-1191.PMID16964263.
Higashi S, Iseki E, Minegishi M, Togo T, Kabuta T, Wada K(Oct 2010).“GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF-1-induced ERK1/2 activation”.J Neurochem115(2): 423-437.doi:10.1111/j.1471-4159.2010.06930.x.PMID20670374.
Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, Hardy J, Houlden H, Singleton A, Schneider SA(Jan 2009).“Characterization of PLA2G6 as a locus for dystonia-parkinsonism”.Ann Neurol65(1): 19-23.doi:10.1002/ana.21415.PMID18570303.
Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M, Hashimoto T, Takashima S, Hattori N(Oct 2010).“Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism”.Neurology75(15): 1356-61.doi:10.1212/WNL.0b013e3181f73649.PMID20938027.
Champy P, Hoglinger GU, Feger J, Gleye C, Hocquemiller R, Laurens A, Guerineau V, Laprevote O, Medja F, Lombes A, Michel PP, Lannuzel A, Hirsch EC, Ruberg M(Jan 2004).“Annonacin, a lipophilic inhibitor of mitochondrial complex I, induces nigral and striatal neurodegeneration in rats: possible relevance for atypical parkinsonism in Guadeloupe”.J neurochem88(1): 63-69.PMID14675150.
Langston,JW;Ballard,P;Tetrud,JW;Irwin,I(Feb 1983).“Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis”.Science219(4587): 979-980.PMID682356.
Standaert,David G.;Young,Anne B.(2006),“Treatment of central nervous system degenerative disorders”,inLaurence L. Brunton, John S. Lazo, Keith L. Parker,Goodman & Gilman's The Pharmacological Basis of Therapeutics(11th ed.),McGraw-Hill,p.529,ISBN0-07-142280-3
Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T(Dec 2009).“Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease”.Nat Genet41(12): 1303-1307.doi:10.1038/ng.485.PMID19915576.
Mitsui J, Mizuta I, Toyoda A, Ashida R, Takahashi Y, Goto J, Fukuda Y, Date H, Iwata A, Yamamoto M, Hattori N, Murata M, Toda T, Tsuji S(May 2009).“Mutations for Gaucher disease confer high susceptibility to Parkinson disease”.Arch Neurol66(5): 571-576.doi:10.1001/archneurol.2009.72.PMID19433656.
Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Durr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG(Oct 2009).“Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease”(free full text).N Eng J Med361(17): 1651-1661.doi:10.1056/NEJMoa0901281.PMID19846850.http://www.nejm.org/doi/full/10.1056/NEJMoa0901281.